Anixa Biosciences, Inc.
Anixa Biosciences, Inc., a pioneering biotechnology firm headquartered in the United States, focuses on innovative solutions in the fields of cancer immunotherapy and infectious disease. Founded in 2017, the company has rapidly established itself as a leader in developing cutting-edge therapies, particularly its unique approach to harnessing the immune system to combat cancer. With a strong emphasis on research and development, Anixa's core products include its proprietary CAR-T cell therapies and vaccine platforms, which are designed to provide targeted and effective treatment options. The company has achieved significant milestones, including collaborations with leading research institutions, positioning itself at the forefront of the biotechnology industry. Anixa Biosciences continues to drive advancements in healthcare, aiming to improve patient outcomes through its groundbreaking scientific innovations.
DitchCarbon Score
How does Anixa Biosciences, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Anixa Biosciences, Inc.'s score of 23 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Anixa Biosciences, Inc.'s reported carbon emissions
Anixa Biosciences, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, the company has not established any documented reduction targets or climate pledges, which suggests a lack of formal commitments to address carbon emissions at this time. As there are no emissions data or reduction initiatives available, it is important to note that Anixa Biosciences may still be in the early stages of developing its climate strategy. In the broader context of the biotechnology industry, many companies are increasingly focusing on sustainability and carbon reduction, often setting science-based targets to align with global climate goals. However, without specific commitments or data, Anixa's current position on climate action remains unclear.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Anixa Biosciences, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
